Skip to main content

Rosetta Genomics to Study MicroRNAs in HIV Infections for NIH

NEW YORK (GenomeWeb News) – Rosetta Genomics will work with the National Institutes of Health to discover microRNAs that may be involved in the viral replication of HIV, the company said today.

Rosetta said it will tap into its microRNA intellectual property and technologies, as well as publicly known human and viral microRNAs, to find out how microRNAs are involved in viral replication in HIV infections and the life cycle of the disease, and whether they may be used as potential novel drug targets for the disease.

The company cited a study published last year in Nature Medicine that showed that microRNAs are involved in suppressing HIV replication and keeping it latent.

Financial terms of the agreement were not released.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.